Healthcare Industry News:  Endoscopic Vessel Harvesting 

Devices Cardiology

 News Release - December 11, 2006

Datascope Announces the CS300(TM) Automatic Balloon Pump and Sensation(TM) 7 Fr. Intra-Aortic Balloon Catheter

MONTVALE, NJ--(Healthcare Sales & Marketing Network)--Dec 11, 2006 -- Datascope Corp. (NASDAQ:DSCP ) announced plans to launch its next generation of intra-aortic balloon therapy products, the Sensation 7 Fr. intra-aortic balloon (IAB) catheter and the CS300 automatic IAB pump. The products will be launched upon receipt of U.S. and European regulatory approvals, which Datascope applied for in late November and early December 2006, respectively.

The Sensation IAB product line, which includes 40cc and 34cc catheters, has the smallest diameter of any IAB catheter available in the U.S. market. The Sensation catheter utilizes fiber optic technology both to reduce the IAB's diameter to 7 Fr. and also to provide a much higher fidelity blood pressure waveform than conventional invasive blood pressure monitoring. This reduced size enables clinicians to deliver counterpulsation therapy to a broader range of patients, including those with smaller peripheral vasculature. Support of this patient population -- smaller adults, diabetics, and individuals with peripheral vascular disease -- has traditionally been challenging for physicians.

The Sensation 7 Fr. catheter also utilizes the new Durathane(TM) balloon membrane. This thinner, yet stronger, membrane is the most abrasion resistant of any IAB, and is designed to give the physician greater confidence in providing longer periods of balloon pumping therapy. In addition, the Sensation 7 Fr. has a substantially lower insertion force than any competitive IAB, facilitating balloon delivery and allowing for faster initiation of therapy.

The CS300 balloon pump, the second in a line of fully automatic pumps produced by Datascope, is an enhancement of the CS100(TM) balloon pump that has been specifically designed to accept and process the Sensation fiber optic signal. Operation of the new pump is extraordinarily simple. Its one-button start-up provides faster initiation of therapy, which is particularly valuable in cardiac emergencies.

"The CS300 balloon pump and Sensation 7 Fr. catheter system represent the highest level of innovation in counterpulsation therapy," said Terry Gunning, President of Datascope's Cardiac Assist Division. "This system delivers a higher standard of care to a broader range of patients. We believe this not only secures our market leadership position in counterpulsation, but also offers the opportunity to expand the market."

Balloon pump therapy, or counterpulsation, is widely used to provide temporary assistance to the heart in a variety of critical care settings, including cardiogenic shock, high-risk coronary angioplasty/stenting procedures, and coronary bypass surgery. Counterpulsation refers to inflation and deflation of an IAB synchronized with the heartbeat in a manner that provides a two-fold assist to the beating heart: increasing its oxygen supply while decreasing its oxygen demand, an intervention that often restores the supply and demand balance necessary for the patient's recovery.

The Sensation 7 Fr. and the CS300 represent another major new product launch for Datascope's Cardiac Assist Division. In January 2006, the division acquired the ClearglideŽ Endoscopic Vessel Harvesting (EVH) product line. EVH devices enable less invasive techniques for harvesting suitable vessels for use in coronary artery bypass grafting. "The CS300 and Sensation 7 Fr. catheter introductions represent a continuation of our strategy to broaden our product portfolio with significant innovations to better serve the needs of interventional cardiologists and cardiovascular surgeons," added Gunning.

About Datascope Corp.

Datascope Corp. is a diversified medical device company that develops, manufactures and markets proprietary products for clinical health care markets in interventional cardiology and radiology, cardiovascular and vascular surgery, anesthesiology, emergency medicine and critical care. The Company has four product lines aggregated into two reporting segments, Cardiac Assist / Monitoring Products and Interventional Products / Vascular Grafts. The Company's products are sold throughout the world through direct sales representatives and independent distributors. Founded in 1964, Datascope is headquartered in Montvale, New Jersey. For news releases, webcasts and other Company information please visit Datascope's website, www.datascope.com.

This press release contains forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements, including but not limited to the company's ability to gain market acceptance for the new Sensation IAB catheter and the CS300 balloon pump, as well as other risks detailed in documents filed by Datascope with the Securities and Exchange Commission.


Source: Datascope

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.